Although CLL remains incurable, advances in the identification and validation of targets, as well as new treatment modalities, hold significant promise. These include the identification of new targets through insights into the pathobiology of CLL, as well as identification of cell surface antigens, and extracellular cytokines and the application of immunology to the development of immune-based treatments. Not only must these new classes of agents and treatment approaches be clinically validated, but their optimal use will require extensive clinical investigation. The next 10 years promise to be an exciting time for clinical research in CLL.
Was this article helpful?